Sign In
Buy UNCY
$5.09
-0.120 (-2.30%)
At Close: Jul 13, 2026
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
08:00pm, Friday, 10'th Jul 2026
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UN
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
08:00pm, Wednesday, 08'th Jul 2026
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors conc
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Unicycive Therapeut
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investors conc
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) on behalf of investors c
UNCY SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
08:00pm, Monday, 06'th Jul 2026
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”)
Unicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
08:42am, Monday, 06'th Jul 2026
Boston, Massachusetts--(Newsfile Corp. - July 6, 2026) - Block & Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential securities law violations. Investors who have lost m
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options
UNCY INVESTIGATION ALERT: Investors Who Lost Money in Unicycive Therapeutics, Inc. Should Contact Block & Leviton
08:45am, Thursday, 02'nd Jul 2026
Boston, Massachusetts--(Newsfile Corp. - July 2, 2026) - Block and Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential
UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
07:00pm, Wednesday, 01'st Jul 2026
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY). The investig
Block & Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: $UNCY) for possible securities law violations. Investors should contact the firm.
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors
12:51pm, Tuesday, 30'th Jun 2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who suffered losses and whether those losses may b
-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor -- -- FDA inspection of third-party facility did not occur during the NDA resubmission rev
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside
02:54am, Thursday, 21'st May 2026
Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved pa
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
07:05am, Tuesday, 12'th May 2026
MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, toda
